Bifogade filer
2024 10 14 Announcement no 27
Kurs
-2,38%
Kurs
-2,38%
Open
0,20
High
0,21
Low
0,20
Close
0,20
Kursutveckling under dagen för detta pressmeddelande
(DKK).
Likviditet
0,15 MDKK
Likviditet
0,15 MDKK
Rel. mcap
0,07%
Antal aktier
728 170
Likviditet under dagen för detta pressmeddelande
Kalender
| Tid* | ||
| 2024-11-15 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-16 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-03 | - | Extra Bolagsstämma 2024 |
| 2024-05-16 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-17 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2024-04-16 | - | Årsstämma |
| 2024-03-20 | - | Bokslutskommuniké 2023 |
| 2023-11-02 | - | Extra Bolagsstämma 2023 |
| 2023-08-16 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-26 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2023-04-25 | - | Årsstämma |
| 2023-03-31 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Extra Bolagsstämma 2022 |
| 2022-08-31 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-26 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2022-04-25 | - | Årsstämma |
| 2022-03-31 | - | Bokslutskommuniké 2021 |
| 2022-01-21 | - | Bokslutskommuniké 2021 |
| 2021-11-10 | - | Extra Bolagsstämma 2021 |
| 2021-08-30 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-03 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2021-04-29 | - | Årsstämma |
| 2020-08-24 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-28 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2020-04-27 | - | Årsstämma |
| 2020-03-30 | - | Bokslutskommuniké 2019 |
| 2019-11-01 | - | Split PEG 10:1 |
| 2019-08-23 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-29 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2019-04-26 | - | Årsstämma |
| 2019-03-29 | - | Bokslutskommuniké 2018 |
| 2019-02-26 | - | Extra Bolagsstämma 2019 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-01 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2018-04-30 | - | Årsstämma |
| 2018-04-06 | - | Bokslutskommuniké 2017 |
| 2017-08-25 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-01 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2017-04-28 | - | Årsstämma |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-12 | - | Kvartalsrapport 2016-Q1 |
| 2016-05-02 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2016-04-29 | - | Årsstämma |
| 2016-03-31 | - | Bokslutskommuniké 2015 |
| 2016-02-24 | - | Split PEG 1:10 |
| 2016-02-18 | - | Extra Bolagsstämma 2016 |
| 2015-10-21 | - | Kvartalsrapport 2015-Q3 |
| 2015-07-15 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-01 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2015-04-30 | - | Årsstämma |
| 2015-04-14 | - | Kvartalsrapport 2015-Q1 |
| 2015-03-31 | - | Bokslutskommuniké 2014 |
| 2015-02-02 | - | Extra Bolagsstämma 2015 |
| 2014-12-22 | - | Extra Bolagsstämma 2014 |
| 2014-11-07 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-15 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-09 | - | Kvartalsrapport 2014-Q1 |
| 2014-04-30 | - | Årsstämma |
| 2014-04-01 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2014-03-31 | - | Bokslutskommuniké 2013 |
| 2013-11-06 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-16 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-07 | - | Kvartalsrapport 2013-Q1 |
| 2013-04-30 | - | Årsstämma |
| 2013-04-01 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2013-03-29 | - | Bokslutskommuniké 2012 |
| 2012-11-06 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-17 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-07 | - | Kvartalsrapport 2012-Q1 |
| 2012-05-01 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2012-04-30 | - | Årsstämma |
| 2012-03-30 | - | Bokslutskommuniké 2011 |
| 2011-11-04 | - | Extra Bolagsstämma 2011 |
| 2011-05-02 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
| 2011-04-29 | - | Årsstämma |
| 2010-05-03 | - | X-dag ordinarie utdelning PEG 0.00 DKK |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Small Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2024-10-14 08:00:03
October 14,2024
Announcement no. 27
Managers’ transactions
Pharma Equity Group A/S has today received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in Pharma Equity Group A/S made by persons discharging managerial responsibilities in Pharma Equity Group and/or persons closely related with them.
| 1. Details of the person discharging managerial responsibilities/person closely associated | |
| a) Name | Christian Vinding Thomsen |
| 2. Reason for the notification | |
| a) Position/status | Chairman of the board of directors |
| b) Initial notification/amendment | Initial notification |
| 3. Details of the issuer | |
| a) Name | Pharma Equity Group A/S |
| b) LEI | 2138008SUI4D917FKN20 |
| c) Trade name | PEG |
| 4. Details of the transaction(s) | |
| a) Description of the financial instrument, type of instrument and Identification code | Shares, ISIN code DK0061155009 |
| b) Nature of the transaction | Subscription by conversion of debt |
| c) Price(s) and volume(s) | Price: DKK 0.25, Volume: 2,139.812 |
| d) Aggregated information - Aggregated volume - Aggregated price | Volume: 2,139.812 Price: DKK 534,953 |
| e) Date of the transaction | 10-10-2024, 09:00 CEST |
| f) Place of the transaction | Nasdaq Copenhagen A/S |
For further information, please contact:
| Thomas Kaas Selsø, CEO of Pharma Equity Group A/S, phone: +45 4022 2114 Christian Vinding Thomsen, Chairman of the Board of Directors of Pharma Equity Group A/S, phone: +45 2622 7222 |
| About Pharma Equity Group A/S Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects. The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. Every effort is currently directed towards ensuring the utmost success and impact of Reponex Pharmaceuticals' medical projects, with an unwavering dedication to improving global healthcare outcomes. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth. |